| Literature DB >> 19895921 |
Eva Veronesi1, Karin E Darpel, Chris Hamblin, Simon Carpenter, Haru-Hisa Takamatsu, Simon J Anthony, Heather Elliott, Peter P C Mertens, Philip S Mellor.
Abstract
The spread of bluetongue virus (BTV) is most successfully controlled by vaccination of susceptible ruminant populations. Currently two different types of BTV vaccines are used for this purpose; inactivated, mostly monovalent vaccine formulations and modified live virus vaccines (MLVs). Clinical signs and viraemia in Dorset Poll sheep vaccinated with BTV-4 and BTV-16 MLVs or inoculated with homogenates of midges (C. sonorensis and C. nubeculosus) previously infected with BTV-4 MLV are presented. All sheep vaccinated with the two MLVs mounted an infectious viraemia lasting for a minimum of 9 up to 23 days post vaccination and developed a range of clinical signs associated with BTV infection. Peak viraemia titres recorded in individual sheep ranged from 3.5 to 6.83 log(10)TCID(50)/ml indicating a high potential for infection of vector insects and onward transmission. The implications of these results are discussed with reference to the current outbreaks of BTV occurring in northern Europe and in relation to the future development of vaccines for this virus. (c) 2009. Published by Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19895921 DOI： 10.1016/j.vaccine.2009.10.107
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641